Literature DB >> 22516831

Airway spray cryotherapy: initial outcomes from a multiinstitutional registry.

David J Finley1, Joe Dycoco, Saiyad Sarkar, William S Krimsky, John T Sherwood, Dominic Dekeratry, Gordon Downie, Joel Atwood, Hiran C Fernando, Valerie W Rusch.   

Abstract

BACKGROUND: Spray cryotherapy (SCT) uses a noncontact system to deliver liquid nitrogen (2 to 4 psi) through an endoscopic catheter. Rapid freezing and thawing of tissue causes cellular death and is also hemostatic. We report the preliminary results from 6 institutions in which SCT was used for the treatment of malignant airway tumors.
METHODS: SCT was performed on patients with symptomatic airway tumors and reviewed retrospectively. Airway narrowing was graded as 25% or smaller, 26% to 50%, 51% to 75%, and exceeding 75%. All events were documented and assessed.
RESULTS: Eighty patients (45 male [56%]) underwent 114 treatments. Median age was 66 years (range, 15 to 90 years). All patients were treated with minimal blood loss. Fifty-eight percent of the cases were outpatient procedures. Airway obstruction exceeded 75% in most of the lesions treated. There were 21 intraoperative events (19%), including hypotension, bradycardia and tachycardia, ST segment changes, desaturation, and an airway tear. Three pneumothoraces occurred, one requiring emergency chest tube placement. Two intraoperative deaths were associated with bradycardia. Three postoperative deaths occurred in patients who were transitioned to comfort care. All but 1 patient had airway patency after treatment.
CONCLUSIONS: SCT can be used in patients with highly vascular tumors, with reduced bleeding complications and a low overall complication rate. Caution is needed before SCT is used on a widespread basis, given the intraoperative complications. Although the potential benefit of SCT is considerable, this needs to be confirmed in larger studies.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22516831     DOI: 10.1016/j.athoracsur.2012.01.112

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  First report of a novel liquid nitrogen adjustable flow spray cryotherapy (SCT) device in the bronchoscopic treatment of disease of the central tracheo-bronchial airways.

Authors:  Robert Browning; Scott Parrish; Saiyad Sarkar; J Francis Turner
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

Review 2.  Current status of spray cryotherapy for airway disease.

Authors:  Ryan F Moore; Deacon J Lile; Abbas E Abbas
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  Techniques of endoscopic airway tumor treatment.

Authors:  Nicolas Guibert; Laurent Mhanna; Sylvain Droneau; Gavin Plat; Alain Didier; Julien Mazieres; Christophe Hermant
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Hemodynamic Instability Following Airway Spray Cryotherapy.

Authors:  Alessia Pedoto; Dawn P Desiderio; David Amar; Robert J Downey
Journal:  Anesth Analg       Date:  2016-11       Impact factor: 5.108

Review 5.  From electrocautery, balloon dilatation, neodymium-doped:yttrium-aluminum-garnet (Nd:YAG) laser to argon plasma coagulation and cryotherapy.

Authors:  Ashutosh Sachdeva; Edward M Pickering; Hans J Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

6.  Spray cryotherapy (SCT): institutional evolution of techniques and clinical practice from early experience in the treatment of malignant airway disease.

Authors:  Robert Browning; J Francis Turner; Scott Parrish
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

7.  Prognosis of patients with primary malignant main stem bronchial tumors: 7,418 cases based on the SEER database.

Authors:  Ke Ma; Fenghao Sun; Xiaodong Yang; Shuai Wang; Lin Wang; Yulin Jin; Yu Shi; Wei Jiang; Cheng Zhan; Qun Wang
Journal:  Onco Targets Ther       Date:  2017-12-22       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.